Search

Your search keyword '"Corradini, Nadege"' showing total 102 results
Start Over Author "Corradini, Nadege" Language english
102 results on '"Corradini, Nadege"'

1. Alveolar soft part sarcomas in young patients: The French national NETSARC+ network experience

Author

Genevois, Anne-Laure, Carton, Matthieu, Jean-Denis, Myriam, Cyrta, Joanna, Corradini, Nadège, Metayer, Lucy, Chemin-Airiau, Claire, Karanian, Marie, Dufresne, Armelle, Pannier, Stéphanie, El Zein, Sophie, Defachelles, Anne-Sophie, Bompas, Emmanuelle, Gantzer, Justine, Honoré, Charles, Noal, Sabine, Héritier, Sébastien, Guillemet, Cécile, Serre, Jill, Le Loarer, François, Pierron, Gaëlle, Merlin, Marie-Sophie, Anract, Philippe, Gomez-Mascard, Anne, Llacer, Carmen, Ducimetière, Françoise, Toulmonde, Maud, Blay, Jean-Yves, and Orbach, Daniel

Published
2024
Full Text
View/download PDF

2. Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS

Author

Chaix, Jordane, Schleiermacher, Gudrun, Corradini, Nadège, André, Nicolas, Thebaud, Estelle, Gambart, Marion, Defachelles, Anne-Sophie, Entz-Werle, Natacha, Chastagner, Pascal, De Carli, Émilie, Ducassou, Stéphane, Landman-Parker, Judith, Adam-de-Beaumais, Tiphaine, Larive, Alicia, Michiels, Stefan, Vassal, Gilles, Valteau-Couanet, Dominique, Geoerger, Birgit, and Berlanga, Pablo

Published
2024
Full Text
View/download PDF

3. Leiomyosarcoma and liposarcoma in young patients: The national netsarc+ network experience

Author

Genevois, Anne-Laure, Carton, Matthieu, Jean-Denis, Myriam, Cyrta, Joanna, Corradini, Nadège, Berlanga, Pablo, Chemin-Airiau, Claire, Honore, Charles, El Zein, Sophie, Defachelles, Anne-Sophie, Bompas, Emmanuelle, Anract, Philippe, Gantzer, Justine, Karanian, Marie, Rome, Angélique, Duffaud, Florence, Chevreau, Christine, Watson, Sarah, Le Cesne, Axel, Llacer, Carmen, Le Loarer, François, Pierron, Gaëlle, Gouin, François, Gomez-Mascard, Anne, Causeret, Sylvain, Ducimetière, Françoise, Kalbacher, Elsa, Toulmonde, Maud, Blay, Jean-Yves, and Orbach, Daniel

Published
2023
Full Text
View/download PDF

4. The role of cancer predisposition syndrome in children and adolescents with very rare tumours

Author

Orbach, Daniel, Brecht, Ines B., Corradini, Nadege, Bouchoucha, Yassine, Roganovic, Jelena, Bourdeaut, Franck, Reguerre, Yves, Kuiper, Roland P., Bressac de Paillerets, Brigitte, Ferrari, Andrea, Virgone, Calogero, Godzinski, Jan, Bisogno, Gianni, Guerrini-Rousseau, Lea, Farinha, Nuno Jorge, Bergamaschi, Luca, Bien, Ewa, Kuhlen, Michaela, Schneider, Dominik T., and Ben Ami, Tal

Published
2023
Full Text
View/download PDF

5. Outcomes in lung-only metastatic rhabdomyosarcoma: An analysis of data from the European paediatric Soft tissue sarcoma Study Group MTS 2008 study

Author

Chisholm, Julia C., Schoot, Reineke A., Cameron, Alison L., Casanova, Michela, Minard-Colin, Veronique, Coppadoro, Beatrice, Garrido, Marta, Rogers, Timothy, Orbach, Daniel, Glosli, Heidi, Ben-Arush, Miriam, Ferman, Sima, Scarzello, Giovanni, van Rijn, Rick R., Hladun, Raquel, Corradini, Nadege, Ferrari, Andrea, Jenney, Meriel, Bisogno, Gianni, and Merks, Johannes H.M.

Published
2023
Full Text
View/download PDF

8. Targeted long-read sequencing of the Ewing sarcoma 6p25.1 susceptibility locus identifies germline-somatic interactions with EWSR1-FLI1 binding

Author

Lee, Olivia W., Rodrigues, Calvin, Lin, Shu-Hong, Luo, Wen, Jones, Kristine, Brown, Derek W., Zhou, Weiyin, Karlins, Eric, Khan, Sairah M., Baulande, Sylvain, Raynal, Virginie, Surdez, Didier, Reynaud, Stephanie, Rubio, Rebeca Alba, Zaidi, Sakina, Grossetête, Sandrine, Ballet, Stelly, Lapouble, Eve, Laurence, Valérie, Pierron, Gaelle, Gaspar, Nathalie, Corradini, Nadège, Marec-Bérard, Perrine, Rothman, Nathaniel, Dagnall, Casey L., Burdett, Laurie, Manning, Michelle, Wyatt, Kathleen, Yeager, Meredith, Chari, Raj, Leisenring, Wendy M., Kulozik, Andreas E., Kriebel, Jennifer, Meitinger, Thomas, Strauch, Konstantin, Kirchner, Thomas, Dirksen, Uta, Mirabello, Lisa, Tucker, Margaret A., Tirode, Franck, Armstrong, Gregory T., Bhatia, Smita, Robison, Leslie L., Yasui, Yutaka, Romero-Pérez, Laura, Hartmann, Wolfgang, Metzler, Markus, Diver, W. Ryan, Lori, Adriana, Freedman, Neal D., Hoover, Robert N., Morton, Lindsay M., Chanock, Stephen J., Grünewald, Thomas G.P., Delattre, Olivier, and Machiela, Mitchell J.

Published
2023
Full Text
View/download PDF

10. Pediatric Tumors and Developmental Anomalies: A French Nationwide Cohort Study

Author

Semeraro, Michaela, Fouquet, Cyrielle, Vial, Yoann, Amiel, Jeanne, Galmiche, Louise, Cretolle, Célia, Blanc, Thomas, Jolaine, Valérie, Garcelon, Nicolas, Entz-Werle, Natacha, Pellier, Isabelle, Vérité, Cécile, Sophie Taque, Coulomb, Aurore, Petit, Arnaud, Corradini, Nadège, Bouazza, Naim, Lacour, Brigitte, Clavel, Jacqueline, Brugières, Laurence, Bourdeaut, Franck, and Sarnacki, Sabine

Published
2023
Full Text
View/download PDF

11. Risk factors in pediatric Malignant Peripheral Nerve Sheath Tumors (MPNST): Results from the French Pediatric Oncology Society (SFCE) cohort

Author

Chaix, Jordane, Karanian, Marie, Corradini, Nadège, Merched, Maria, Larousserie, Frédérique, Galmiche, Louise, Lacour, Brigitte, Marie-Cardine, Aude, Defachelles, Anne-Sophie, Berlanga, Pablo, Rome, Angélique, Thébaud, Estelle, Bernier-Chastagner, Valérie, Brisse, Hervé J., Hameury, Frédéric, Wolkenstein, Pierre, Ducassou, Stéphane, Orbach, Daniel, and Vérité, Cécile

Published
2023
Full Text
View/download PDF

12. Desmoid type fibromatosis in pediatric and young adults from French databases: Clinical characteristics and initial outcome according to age

Author

Bouttefroy, Séverine, Penel, Nicolas, Orbach, Daniel, Minard-Colin, Véronique, Le Cesne, Axel, Blay, Jean-Yves, Marec-Berard, Perrine, Verité, Cécile, Laurence, Valérie, Piperno-Neumann, Sophie, Defachelles, Anne-Sophie, Bompas, Emmanuelle, Chevreau, Christine, Duffaud, Florence, Salas, Sébastien, Morelle, Magali, Jean-Denis, Myriam, Italiano, Antoine, Bonvalot, Sylvie, and Corradini, Nadège

Published
2023
Full Text
View/download PDF

13. Locally aggressive rarely metastazing tumors and low-grade sarcoma in children, adolescents and young adults: The benefits of a national network

Author

Brisset, Claire, Carton, Matthieu, Chemin-Airiau, Claire, Karanian, Marie, Vérité, Cécile, Corradini, Nadege, Mascard, Eric, Gouin, François, Bonvalot, Sylvie, Minard-Colin, Véronique, Fayard, Cindy, Pannier, Stéphanie, Blay, Jean-Yves, Le Nail, Louis-Romée, Le Loarer, François, Brisse, Hervé J., Chotel, Franck, Pierron, Gaëlle, Tirode, Franck, Defachelles, Anne-Sophie, Toulmonde, Maud, and Orbach, Daniel

Published
2022
Full Text
View/download PDF

15. Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of GSF-GETO and SFCE, with the support of the NETSARC+ network

Author

Bompas, Emmanuelle, Martin, Valentine, Meniai, Fatima, Toulmonde, Maud, Marec-Berard, Perrine, Claude, Line, Ducimetiere, Françoise, Chargari, Cyrus, Minard-Colin, Véronique, Corradini, Nadège, Laurence, Valérie, Piperno-Neumann, Sophie, Defachelles, Anne-Sophie, Bernier, Valérie, Italiano, Antoine, Orbach, Daniel, Blay, Jean-Yves, Gaspar, Nathalie, and Berlanga, Pablo

Published
2021
Full Text
View/download PDF

16. Treatment at relapse for synovial sarcoma of children and adolescents: A multi‐institutional European retrospective analysis.

Author

Ferrari, Andrea, Orbach, Daniel, Bergamaschi, Luca, Schoot, Reineke A., van Noesel, Max M, Di Carlo, Daniela, Bisogno, Gianni, Alaggio, Rita, Milano, Giuseppe Maria, Chiaravalli, Stefano, Fuccillo, Fernando, Laurence, Valerie, Corradini, Nadege, Gasparini, Patrizia, Vennarini, Sabina, Pasquali, Sandro, and Casanova, Michela

Published
2024
Full Text
View/download PDF

17. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study

Author

Geoerger, Birgit, Zwaan, C Michel, Marshall, Lynley V, Michon, Jean, Bourdeaut, Franck, Casanova, Michela, Corradini, Nadège, Rossato, Gianluca, Farid-Kapadia, Mufiza, Shemesh, Colby S, Hutchinson, Katherine E, Donaldson, Francis, Liao, Minlei, Caron, Hubert, and Trippett, Tanya

Published
2020
Full Text
View/download PDF

21. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study

Author

Gaspar, Nathalie, Occean, Bob-Valéry, Pacquement, Hélène, Bompas, Emmanuelle, Bouvier, Corine, Brisse, Hervé J., Castex, Marie-Pierre, Cheurfa, Nadir, Corradini, Nadège, Delaye, Jessy, Entz-Werlé, Natacha, Gentet, Jean-Claude, Italiano, Antoine, Lervat, Cyril, Marec-Berard, Perrine, Mascard, Eric, Redini, Françoise, Saumet, Laure, Schmitt, Claudine, Tabone, Marie-Dominique, Verite-Goulard, Cécile, Le Deley, Marie-Cécile, Piperno-Neumann, Sophie, and Brugieres, Laurence

Published
2018
Full Text
View/download PDF

24. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial

Author

Piperno-Neumann, Sophie, Le Deley, Marie-Cécile, Rédini, Françoise, Pacquement, Hélène, Marec-Bérard, Perrine, Petit, Philippe, Brisse, Hervé, Lervat, Cyril, Gentet, Jean-Claude, Entz-Werlé, Natacha, Italiano, Antoine, Corradini, Nadège, Bompas, Emmanuelle, Penel, Nicolas, Tabone, Marie-Dominique, Gomez-Brouchet, Anne, Guinebretière, Jean-Marc, Mascard, Eric, Gouin, François, Chevance, Aurélie, Bonnet, Naïma, Blay, Jean-Yves, and Brugières, Laurence

Published
2016
Full Text
View/download PDF

25. Treatment at Relapse for Synovial Sarcoma of Children, Adolescents and Young Adults: From the State of Art to Future Clinical Perspectives.

Author

Ferrari, Andrea, Berlanga, Pablo, Gatz, Susanne Andrea, Schoot, Reineke A, van Noesel, Max M, Hovsepyan, Shushan, Chiaravalli, Stefano, Bergamaschi, Luca, Minard-Colin, Veronique, Corradini, Nadege, Alaggio, Rita, Gasparini, Patrizia, Brennan, Bernadette, Casanova, Michela, Pasquali, Sandro, and Orbach, Daniel

Subjects
YOUNG adults, SYNOVIOMA, TEENAGERS, CHILD patients, INVESTIGATIONAL therapies, DISEASE relapse
Abstract

While the overall prognosis is generally quite satisfactory in children, adolescents and young adults with localised synovial sarcoma at first diagnosis, the outcome remains poor for patients after relapse. Conversely to the front-line standardised treatment options, patients with relapse generally have an individualised approach and to date, there is still a lack of consensus regarding standard treatment approaches. Studies on relapsed synovial sarcoma were able to identify some prognostic variables that influence post-relapse survival, in order to plan risk-adapted salvage protocols. Treatment proposals must consider previous first-line treatments, potential toxicities, and the possibility of achieving an adequate local treatment by new surgery and/or re-irradiation. Effective second-line drug therapies are urgently needed. Notably, experimental treatments such as adoptive engineered TCR-T cell immunotherapy seem promising in adults and are currently under validation also in paediatric patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Intra‐abdominal desmoplastic small round cell tumor: The European pediatric Soft tissue sarcoma Study Group (EpSSG) experience.

Author

Berlanga, Pablo, Orbach, Daniel, Schoot, Reineke A., Casanova, Michela, Alaggio, Rita, Corradini, Nadege, Brennan, Bernadette, Ramirez‐Villar, Gema L., Hjalgrim, Lisa Lyngsie, Chisholm, Julia C., Bisogno, Gianni, Coppadoro, Beatrice, Safwat, Akmal, Merks, Johannes H. M., Burrieza, Gabriela Guillen, van Noesel, Max M., and Ferrari, Andrea

Published
2023
Full Text
View/download PDF

27. Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas: Standard of Care and Treatment Recommendations from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

Author

Ferrari,Andrea, Brennan,Bernadette, Casanova,Michela, Corradini,Nadege, Berlanga,Pablo, Schoot,Reineke A, Ramirez-Villar,Gema L, Safwat,Akmal, Guillen Burrieza,Gabriela, Dall'Igna,Patrizia, Alaggio,Rita, Lyngsie Hjalgrim,Lisa, Gatz,Susanne Andrea, Orbach,Daniel, and van Noesel,Max M

Subjects
Cancer Management and Research
Abstract

Andrea Ferrari,1 Bernadette Brennan,2 Michela Casanova,1 Nadege Corradini,3 Pablo Berlanga,4 Reineke A Schoot,5 Gema L Ramirez-Villar,6 Akmal Safwat,7 Gabriela Guillen Burrieza,8 Patrizia Dall’Igna,9 Rita Alaggio,10 Lisa Lyngsie Hjalgrim,11 Susanne Andrea Gatz,12 Daniel Orbach,13 Max M van Noesel5 1Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; 2Pediatric Oncology, Royal Manchester Children’s Hospital, Manchester, UK; 3Department of Pediatric Oncology, Institut d’Hematologie et d’Oncologie Pédiatrique/Centre, Léon Bérard, Lyon, France; 4Department of Pediatric and Adolescent Oncology, Gustave-Roussy, Cancer Campus, Université Paris-Saclay, Villejuif, France; 5Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; 6Pediatric Oncology Unit, Hospital Universitario Virgen del Rocío, Seville, Spain; 7Oncology Department and Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark; 8Surgical Oncology and Neonatal Surgery, Pediatric Surgery Department, Hospital Infantil Universitari Vall d’Hebron, Barcelona, Spain; 9Department of Emergencies and Organ Transplantation, Pediatric Surgery, University of Bari, Bari, Italy; 10Pathology Department, Ospedale Pediatrico Bambino Gesù IRCCS, Rome, Italy; 11Department of Pediatrics and Adolescent Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; 12Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; 13SIREDO Oncology Center, Institut Curie, PSL University, Paris, FranceCorrespondence: Andrea Ferrari, Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Via G. Venezian, 1, Milan, MI, 20133, Italy, Tel +39 02 23902588, Fax +39 02 23902648, Email andrea.ferrari@istitutotumori.mi.itAbstract: This paper describes the standard of care for patients with non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) and the therapeutic recommendations developed by the European paediatric Soft tissue sarcoma Study Group (EpSSG). NRSTS form a very mixed group of mesenchymal extraskeletal malignancies. Their rarity, heterogeneity, and aggressiveness make the management of children and adolescents with these tumors complex and challenging. The overall cure rate for patients with NRSTS is around 70%, but survival depends on several prognostic variables, such as histotype and tumor grade, extent of disease and stage, tumor size, and tumor site. While surgery remains the mainstay of treatment for most of these tumors, a multimodal therapeutic approach including radiotherapy and chemotherapy is required in many cases. The EpSSG NRSTS 2005 study was the first prospective protocol tailored specifically to NRSTS. Together with the ARST0332 study developed by the North-American Soft Tissue Sarcoma Committee of the Children’s Oncology Group (COG), the EpSSG NRSTS 2005 study currently represents the benchmark for these tumors, establishing risk-adapted standards of care. The EpSSG has developed common treatment recommendations for the large group of adult-type NRSTS (including synovial sarcoma), and specific treatment recommendations for other particular adult-type histologies (ie, alveolar soft-part sarcoma, clear cell sarcoma and dermatofibrosarcoma protuberans); other highly malignant tumors with a biology and clinical behavior differing from those of adult-type NRSTS (ie, rhabdoid tumors and desmoplastic small round cell tumor); and soft tissue tumors of intermediate malignancy (ie desmoid-type fibromatosis, inflammatory myofibroblastic tumors, and infantile fibrosarcoma). New effective drugs are needed for patients whose NRSTS carries the worst prognosis, ie, those with unresectable tumors, metastases at diagnosis, or relapsing disease. Progress in this area relies on our ability to develop international integrated prospective collaborations, both within existing pediatric oncology networks and, importantly, between the communities of specialists treating pediatric and adult sarcoma.Keywords: non-rhabdomyosarcoma soft tissue sarcomas, NRSTS, EpSSG, treatment, recommendations, pediatric

Published
2022

28. Metastatic adult‐type non‐rhabdomyosarcoma soft tissue sarcomas in children and adolescents: A cohort study from the European paediatric Soft tissue sarcoma Study Group.

Author

Ferrari, Andrea, Orbach, Daniel, Casanova, Michela, van Noesel, Max M., Berlanga, Pablo, Brennan, Bernadette, Corradini, Nadege, Schoot, Reineke A., Ramirez‐Villar, Gema L., Hjalgrim, Lisa Lyngsie, Alaggio, Rita, Guillen Burrieza, Gabriela, Safwat, Akmal, Cameron, Alison L., van Rijn, Rick R., Minard‐Colin, Veronique, Zanetti, Ilaria, Bisogno, Gianni, Chisholm, Julia C., and Merks, Johannes H. M.

Subjects
SARCOMA, PEDIATRICS, COHORT analysis, CANCER invasiveness, METASTASIS
Abstract

Background: Limited data exist on the clinical behavior of pediatric non‐rhabdomyosarcoma soft tissue sarcomas (NRSTS) with distant metastases at onset, and a clear standard of care has not yet been defined. Methods: This cohort study reports on pediatric adult‐type metastatic NRSTS enrolled in two concurrent prospective European studies, i.e., the randomized BERNIE study and the single‐arm MTS 2008 study developed by the European paediatric Soft tissue sarcoma Study Group. Treatment programs were originally designed for patients with metastatic rhabdomyosarcoma, i.e., nine courses of multidrug chemotherapy (with or without bevacizumab in the BERNIE study), followed by 12 cycles of maintenance therapy, whereas radiotherapy and/or surgery (on primary tumor and/or metastases) were delayed until after seven courses of chemotherapy had been administered. Results: The study included 61 patients <21 years old treated from July 2008 to December 2016. The lung was the site of metastases in 75% of the cases. All patients received multi‐agent chemotherapy, 44% had local therapy to primary tumor, and 18% had treatment of metastases. Median time to progression/relapse was 6 months. A high rate of tumor progression was observed during the initial part of the chemotherapy program. With a median follow‐up of 41.5 months (range, 2–111 months), 3‐year event‐free survival and overall survival were 15.4% (95% confidence interval [CI], 7.6–25.7) and 34.9% (95% CI, 22.7–47.5), respectively. There were no statistically significant differences in outcome depending on the type of treatment administered. Conclusions: The study confirmed the overall poor outcome for patients with metastatic NRSTS, whose treatment remains a challenge. Plain Language Summary: Pediatric non‐rhabdomyosarcoma soft tissue sarcomas form a heterogeneous group of rare tumors.Although recent international studies have defined the standard of care for patients with localized disease, limited data are available on the clinical behavior of patients with distant metastases.This study on 61 metastatic cases treated on two prospective European protocols confirms that the chances of survival of such patients are often dismal and a standard treatment is still lacking. This is a large cohort study reporting on pediatric metastatic non‐rhabdomyosarcoma soft tissue sarcomas (NRSTS) enrolled in two concurrent prospective European studies. The study confirmed the overall poor outcome for patients with metastatic NRSTS, whose treatment remains a challenge. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

29. Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma – A report from the Société Française des Cancers et leucémies de l’Enfant et de l’adolescent (SFCE)

Author

Minard-Colin, Véronique, Ichante, Jean-Laurent, Nguyen, Laurent, Paci, Angelo, Orbach, Daniel, Bergeron, Christophe, Defachelles, Anne-Sophie, André, Nicolas, Corradini, Nadège, Schmitt, Claudine, Tabone, Marie-Dominique, Blouin, Pascale, Sirvent, Nicolas, Goma, Gisele, Geoerger, Birgit, and Oberlin, Odile

Published
2012
Full Text
View/download PDF

37. Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.

Author

Bautista, Francisco, Paoletti, Xavier, Rubino, Jonathan, Brard, Caroline, Rezai, Keyvan, Nebchi, Souad, Andre, Nicolas, Aerts, Isabelle, De Carli, Emilie, van Eijkelenburg, Natasha, Thebaud, Estelle, Corradini, Nadege, Defachelles, Anne-Sophie, Ducassou, Stephane, Morscher, Raphael J, Vassal, Gilles, and Geoerger, Birgit

Published
2021
Full Text
View/download PDF

38. Local staging and treatment in extremity rhabdomyosarcoma. A report from the EpSSG‐RMS2005 study.

Author

Terwisscha van Scheltinga, Sheila E. J., Wijnen, Marc H. W. A., Martelli, Hélène, Rogers, Timothy, Mandeville, Henry, Gaze, Mark N., McHugh, Keiran, Corradini, Nadege, Orbach, Daniel, Jenney, Meriel, Kelsey, Anna, Chisholm, Julia, Gallego, Soledad, Glosli, Heidi, Ferrari, Andrea, Zanetti, Ilaria, De Salvo, Gian Luca, Minard‐Colin, Veronique, Bisogno, Giani, and van Noesel, Max M.

Subjects
RHABDOMYOSARCOMA, TUMOR surgery, LYMPH nodes, SENTINEL lymph node biopsy, THERAPEUTICS
Abstract

Rhabdomyosarcoma of the extremities present with two main challenges: correct evaluation of initial regional nodal involvement and define adequate local treatment. Methods: Pediatric patients with localized rhabdomyosarcoma of the extremity included in the EpSSG‐RMS2005 study between 2005 and 2014 were evaluated for staging, treatment, and survival. The outcome was compared to the preceding European SIOP‐MMT studies. Results: Of the 162 patients included, histology was unfavorable in 113 (70%), 124 (77%) were younger than 10 years, 128 (79%) were IRS III, and 47 (29%) were node‐positive. A regional node biopsy was performed in 97 patients (60%) and modified the lymph node stage in 15/97 (16%). Primary and delayed surgery was performed in 155 (96%) and radiotherapy delivered in 118 (73%) patients. Relapse occurred in 61 cases (38%), local in 14 (23%), regional in 13 (21%), distant in 22 (36%), and combined relapse in 12 (20%) with five progressive diseases (8%) and four secondary tumors (7%). Five‐year event free (EFS) and overall survival (OS) were 58.4% (95%CI, 50.3‐65.7) and 71.7% (63.6‐78.4), respectively. In the previous studies MMT89 and MMT95, tumor surgery was performed in 32/53 (60%) and 74/82(90%), respectively, and radiotherapy delivered in 13/53 (25%) and 26/82 (30%), respectively. Five‐year EFS and OS were 35.6%, and 50.3% in MMT89 and 54.3% and 68.2% in the MMT95 study. Conclusions: Even if the lymph node staging was not always complete according to the RMS2005 protocol, node sampling changed lymph node status in a significant number of patients. Despite the higher rate of patients treated with locoregional radiotherapy, survival in RMS2005 did not improve compared to the previous European SIOP‐MMT95 study. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

42. List of Contributors

Author

Alix-Panabieres, Catherine, Arlt, Matthias J.E., Bataille, Regis, Bedard, Gillian, Berthold, Dominik R., Bianco, Paolo, Blanchard, Frédéric, Blay, Jean-Yves, Bolton, Damien, Bolzoni, Marina, Born, Walter, Botter, Sander M., Bouvier, Corinne, Brounais-Le Royer, Bénédicte, Brown, Nicola J., Buijs, Jeroen T., Camacho, Daniel F., Campbell, Preston, Chappard, Daniel, Chartier, Stephane, Chou, Hong, Chow, Edward, Chow, Ronald, Christoulas, Dimitrios, Cleton-Jansen, Anne-Marie, Clézardin, Philippe, Clohisy, Denis R., Coleman, Robert, Corradini, Nadège, Croset, Martine, de Pinieux, Gonzague, Derbel, Olfa, Desiderio, Vincenzo, Edwards, James R., Elefteriou, Florent, Fealk, Michelle, Flanagan, Adrienne M., Fournier, Pierrick G.J., Fromigué, Olivia, Fuchs, Bruno, Gao, Dingcheng, Gikas, Panagiotis D., Giuliani, Nicola, Gnant, Michael, Gomez-Brouchet, Anne, Gosheger, Georg, Gouin, François, Guise, Theresa A., Harada, Shuko, Hardes, Jendrik, Hauben, Esther I., He, Wei, Herrera, Fernanda G., Heymann, Marie-Françoise, Hicks, David G., Hogendoorn, Pancras C.W., Holen, Ingunn, Ilaslan, Hakan, Isidor, Bertrand, Jacques, Camille, Juàrez, Patricia, Junankar, Simon, Kabelitz, Dieter, Kalyan, Shirin, Kontny, Udo, Knuutila, Sakari, La Noce, Marcella, Lamora, Audrey, Lamoureux, Francois, Lao, Nicholas, Lawrentschuk, Nathan, Lawson, Michelle A., Lecanda, Fernando, Lee, Jiyun, Lézot, Frédéric, Li, Shibo, Lissat, Andrej, Ludwig, Joseph, Määttä, Jorma A., Mallinson, Paul I., Mantyh, Patrick W., Marie, Pierre J., Mavrogenis, Andreas F., Mikkilineni, Himabindu, Mittal, Vivek, Modrowski, Dominique, Munk, Peter L., Navet, Benjamin, Niini, Tarja, O’Donnell, Patrick W., Odri, Guillaume, Ory, Benjamin, Ouellette, Hugue A., Paino, Francesca, Pantel, K., Papaccio, Federica, Papaccio, Gianpaolo, Park, Paul C., Paterson, Alexander H.G., Patiño-García, Ana, Pienta, Kenneth J., Popovic, Marko, Rajarubendra, Nieroshan, Redini, Françoise, Reeves, Kimberley J., Reisinger, Clemens, Riminucci, Mara, Rodriguez, Lidia, Rogers, Michael J., Ruggieri, Pietro, Sacchetti, Benedetto, Seibel, Markus J., Selvarajah, Shamini, Siegal, Gene P., Sousa, Sofia, Squire, Jeremy A., Sternenberger, Andrea R., Streitbuerger, Arne, Stresing, Verena, Sundaram, Murali, Talbot, Julie, Tang, Ping, Tawadros, Thomas, Terpos, Evangelos, Thomas, Christian, Thompson, Erik W., Thompson, Michelle L., Tirabosco, Roberto, Tirino, Virginia, Tirode, Franck, Trichet, Valèrie, van der Horst, Geertje, van der Pluijm, Gabri, Verrecchia, Franck, Walkley, Carl R., Wei, Shi, and Zielenska, Maria

Published
2015
Full Text
View/download PDF

49. Role of 18F-FDG-PET/CT in the staging of metastatic rhabdomyosarcoma: a report from the European paediatric Soft tissue sarcoma Study Group.

Author

Mercolini, Federico, Zucchetta, Pietro, Jehanno, Nina, Corradini, Nadege, Van Rijn, Rick R., Rogers, Timothy, Cameron, Alison, Scarzello, Giovanni, Coppadoro, Beatrice, Minard-Colin, Veronique, Gallego, Soledad, Chisholm, Julia, Merks, J.Hans, and Bisogno, Gianni

Subjects
*RHABDOMYOSARCOMA, *METASTASIS, *TUMOR classification, *RADIONUCLIDE imaging, *RADIOPHARMACEUTICALS, *DESCRIPTIVE statistics, *DEOXY sugars
Abstract

Initial staging of rhabdomyosarcoma is crucial for prognosis and to tailor the treatment. The standard radiology workup (SRW) includes magnetic resonance imaging, chest computed tomography (CT) and bone scintigraphy, but 18 Fluorine-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) (18F-FDG-PET/CT (PET-CT)) use is increasing. The aim of this study was to evaluate the impact of PET-CT in the initial staging of patients with metastatic rhabdomyosarcoma enrolled in the European protocol MTS2008. Two authors retrospectively reviewed the SRW and PET-CT reports comparing the number and sites of metastases detected. For bone marrow involvement, PET-CT and bone marrow aspirates/biopsies were compared. Among 263 metastatic patients enrolled from October 2008 to December 2016, 121 had PET-CT performed at diagnosis, and for 118 of 121 patients, both PET-CT and radiological reports were available for review. PET-CT showed higher sensitivity than SRW in the ability to detect locoregional (96.2% versus 78.5%, P value = 0.0013) and distant lymph node involvement (94.8% versus 79.3%, P value = 0.0242), but sensitivity was lower for intrathoracic sites (lung 79.6% versus 100%, P value = 0.0025). For bone metastasis, PET-CT was more sensitive than bone scintigraphy (96.4% versus 67.9%, P value = 0.0116). The PET-CT sensitivity and specificity to detect marrow involvement were 91.8% and 93.8%, respectively. The mean number of metastatic sites was 1.94 (range 0–5) with PET-CT and 1.72 (range 0–5) with SRW. In four patients (3.4%), PET-CT changed the staging from localised to metastatic disease. PET can identify metastatic disease not evident on SRW in a small number of patients. This is because of its higher ability to recognise lymph node and bone involvement. Chest CT remains essential to detect lesions in intrathoracic sites, which can be performed in a one stop-shot routine examination or on a dedicated chest CT scan. PET-CT could replace bone scintigraphy to study bone involvement. • Positron emission tomography (PET)/computed tomography (CT) in the staging of rhabdomyosarcoma is increasingly used. • PET/CT is more sensitive than conventional radiology in detecting nodal metastases. • Chest CT is essential for the evaluation of intrathoracic lesions. • PET/CT could replace bone scintigraphy to study bone involvement. • Systematic use of PET/CT will modestly increase the number of metastatic patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

50. Non-parameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: Experience of the European paediatric Soft tissue sarcoma Study Group (EpSSG) – RMS2005 study.

Author

Glosli, Heidi, Bisogno, Gianni, Kelsey, Anna, Chisholm, Julia C., Gaze, Mark, Kolb, Frederic, McHugh, Kieran, Shipley, Janet, Gallego, Soledad, Merks, Johannes H.M., Smeele, Ludi E., Mandeville, Henry, Ferrari, Andrea, Minard-Colin, Veronique, Corradini, Nadege, Jenney, Meriel, Zanetti, Ilaria, De Salvo, Gian L., and Orbach, Daniel

Subjects
*HEAD tumors, *CONFIDENCE intervals, *CANCER chemotherapy, *CANCER relapse, *RISK assessment, *SURVIVAL analysis (Biometry), *DESCRIPTIVE statistics, *NECK tumors, *EVALUATION, *CHILDREN
Abstract

The primary aim of this study was to analyse and evaluate the impact of different local treatments on the pattern of relapse in children with primary head and neck non-parameningeal (HNnPM) rhabdomyosarcoma (RMS), treated in the European paediatric Soft tissue sarcoma Study Group (EpSSG) RMS2005 study. The secondary aim was to assess whether current risk stratification is valid for this specific site. This study includes all patients with localised HNnPM RMS enrolled in the RMS2005 study between 2005 and 2016. Treatment comprised chemotherapy adapted to risk group, with local surgery and/or radiation therapy. The main outcome measures were event-free survival (EFS) and overall survival (OS). A total of 165 patients were identified; the median age was 6.4 years (range, 0.1–25). The most common tumour sites were cheek/chin (22%) and nasal ala/nasolabial fold (20%). Histology was unfavourable for 40%, and regional nodal involvement present in 26%. Local therapy included surgery (58%) and/or radiotherapy (72%) to primary tumour and/or regional lymph nodes. After a median follow-up of 66 months (range, 6–158), 42 patients experienced an event, and 17 are still alive. Tumour events were frequent in oral primary (36%), parotid site (26%), cheek/chin (24%), and nasal ala/nasolabial fold (24%) and included locoregional failure in 84% of cases. The 5-year EFS and OS were 75% (95% confidence interval [CI]: 67.3–81.2) and 84.9% (95% CI: 77.5–89.7), respectively. Favourable histology was associated with a better EFS (82.3% versus 64.6%; p = 0.02) and nodal spread with a worse OS (88.6% versus 76.1%; p = 0.04). Different sublocations within the HNnPM primary did not have significant impact on outcome. Locoregional relapse/progression is the main tumour failure event in this site. Despite frequent unfavourable risk factors, HNnPM RMS remains a favourable location in the context of a risk-adapted strategy. • Large prospective analysis of children with head and neck rhabdomyosarcoma. • Adapted strategy according to risk factors allows favourable outcome. • Unfavourable histology and cervical lymph node involvement is frequent in this site. • Locoregional relapse/progression is the main tumour failure event. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results